リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery : systematic review and meta-analysis of observational studies.」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Malignant transformation of WHO grade I meningiomas after surgery or radiosurgery : systematic review and meta-analysis of observational studies.

NAKASU Satoshi 00135477 0000-0001-8719-9806 NOTSU Akifumi NA Kiyong NAKASU Yoko 10135478 滋賀医科大学

2020.10.16

概要

Background:
The incidence and clinical features of the malignant transformation of benign meningiomas are poorly understood. This study examined the risk of the malignant transformation of benign meningiomas after surgery or stereotactic radiosurgery.
Methods:
We systematically reviewed studies published between 1979 and 2019 using PubMed, Scopus, and other sources. We analyzed pooled data according to the PRISMA guideline to clarify the incidence rate of malignant transformation (IMT) and factors affecting malignant transformation in surgically or radiosurgically treated benign meningiomas.
Results:
IMT was 2.98/1000 patient-years (95% confidence interval [CI] = 1.9-4.3) in 13 studies in a single-arm meta-analysis. Although the evidence level of the included studies was low, the heterogeneity of the incidence was mostly explained by the tumor location. In meta-regression analysis, skull base tumors had a significantly lower IMT than non-skull base tumors, but no gender association was observed. IMT after radiosurgery in 9 studies was 0.50/1000 person-years (95% CI = 0.02-1.38). However, a higher proportion of skull base tumors, lower proportion of males, and lower salvage surgery rate were observed in the radiosurgery group than in the surgery group. The median time to malignant change was 5 years (interquartile range = 2.5-8.2), and the median survival after malignant transformation was 4.7 years (95% CI = 3.7-8) in individual case data.
Conclusion:
IMT of benign meningioma was significantly affected by the tumor location. Radiosurgery did not appear to increase IMT, but exact comparisons were difficult because of differences in study populations.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Nakasu S, Nakasu Y. Natural history of meningiomas: review with meta- analyses. Neurol Med Chir (Tokyo). 2020;60(3):109–120.

2. Nakasu S, Nakasu Y, Fukami T, Jito J, Nozaki K. Growth curve anal- ysis of asymptomatic and symptomatic meningiomas. J Neurooncol. 2011;102(2):303–310.

3. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22–39.

4. Champeaux C, Houston D, Dunn L, Resche-Rigon M. Intracranial WHO grade I meningioma: a competing risk analysis of progression and disease-specific survival. Acta Neurochir (Wien). 2019. doi:10.1007/ s00701-019-04096-9. Online ahead of print.

5. Mubeen B, Makhdoomi R, Nayil K, et al. Clinicopathological character- istics of meningiomas: experience from a tertiary care hospital in the Kashmir valley. Asian J Neurosurg. 2019;14(1):41–46.

6. Nakasu S, Fukami T, Jito J, Nozaki K. Recurrence and regrowth of benign meningiomas. Brain Tumor Pathol. 2009;26(2):69–72.

7. Hashimoto N, Rabo CS, Okita Y, et al. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg. 2012;116(3): 574–580.

8. Voß KM, Spille DC, Sauerland C, et al. The Simpson grading in menin- gioma surgery: does the tumor location influence the prognostic value? J Neurooncol. 2017;133(3):641–651.

9. Meling TR, Da Broi M, Scheie D, Helseth E. Meningiomas: skull base versus non-skull base. Neurosurg Rev. 2019;42(1):163–173.

10. Bi WL, Greenwald NF, Abedalthagafi M, et al. Genomic landscape of high-grade meningiomas. NPJ Genom Med. 2017;2:15.

11. Gao F, Shi L, Russin J, et al. DNA methylation in the malignant transfor- mation of meningiomas. PLoS One. 2013;8(1):e54114.

12. Champeaux C, Wilson E, Shieff C, Khan AA, Thorne L. WHO grade II me- ningioma: a retrospective study for outcome and prognostic factor as- sessment. J Neurooncol. 2016;129(2):337–345.

13. Champeaux C, Jecko V, Houston D, et al. Malignant meningioma: an international multicentre retrospective study. Neurosurgery. 2019;85(3):E461–E469.

14. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008;79(5):574–580.

15. Ketter R, Henn W, Niedermayer I, et al. Predictive value of progression- associated chromosomal aberrations for the prognosis of meningiomas_ a retrospective study of 198 cases. J Neurosurg. 2001;95(4):601–607.

16. Al-Mefty O, Kadri PA, Pravdenkova S, Sawyer JR, Stangeby C, Husain M. Malignant progression in meningioma: documentation of a series and analysis of cytogenetic findings. J Neurosurg. 2004;101(2):210–218.

17. Perez-Magan E, Rodriguez de Lope A, Ribalta T, et al. Differential ex- pression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol. 2010;12(12):1278–1290.

18. Harmancı AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2018;20(9):16215.

19. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. Brain Pathol. 2014;24(2):184–189.

20. Juratli TA, Thiede C, Koerner MVA, et al. Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget. 2017;8(65):109228–109237.

21. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol. 1975;208(4):279–298.

22. Jääskeläinen J, Haltia M, Servo A. Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol. 1986;25(3):233–242.

23. Schiffer D, Ghimenti C, Fiano V. Absence of histological signs of tumor progression in recurrences of completely resected meningiomas. J Neurooncol. 2005;73(2):125–130.

24. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recur- rence in patients with non-skull base and skull base meningiomas. J Neurosurg. 2010;112(5):925–933.

25. Yeon EK, Sung JY, Do SI, Park BJ, Kim EJ, Na K. Clinicoradiological features of recurrent meningioma with high grade transformation. Anticancer Res. 2019;39(11):6299–6305.

26. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant trans- formation and new primary tumours after therapeutic radiation for be- nign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43(4):289–294.

27. Wolf A, Naylor K, Tam M, et al. Risk of radiation-associated intracranial malignancy after stereotactic radiosurgery: a retrospective, multicentre, cohort study. Lancet Oncol. 2019;20(1):159–164.

28. Pollock BE, Stafford SL, Link MJ, Brown PD, Garces YI, Foote RL. Single- fraction radiosurgery of benign intracranial meningiomas. Neurosurgery. 2012;71(3):604–612; discussion 613.

29. Santacroce A, Walier M, Regis J, et al. Long-term tumor control of be- nign intracranial meningiomas after radiosurgery in a series of 4565 pa- tients. Neurosurgery. 2012;70(1):32–39; discussion 39.

30. Celtikci E, Kaymaz AM, Akgul G, Karaaslan B, Emmez OH, Borcek A. Retrospective analysis of 449 intracranial meningioma patients op- erated between 2007 and 2013 at a single institute. Turk Neurosurg. 2018;28(1):1–6.

31. Zulch KJ. Histological Typing of Tumours of the Central Nervous System. Geneva: World Health Organization; 1979.

32. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System, 2nd ed. Berlin, Germany: Springer- Verlag; 1993.

33. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas. In: Kleihues P and Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC; 2000.

34. Perry A, Louis DA, Scheithauer BW, Budka H, von Demling A. Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC; 2007:163–172.

35. Perry A, Louis DN, Budka H, et al. Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds. WHO Classification of Tumours of the Central Nervous System, revised 4th ed. Lyon, France: IARC; 2016:232–245.

36. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.

37. Kojima T, Waga S, Itoh H, Matsubara T, Kuga Y. [Clinical analysis of ma- lignant meningiomas]. No Shinkei Geka. 1990;18(10):939–946.

38. Chan RC, Thompson GB. Morbidity, mortality, and quality of life following surgery for intracranial meningiomas. J Neurosurg. 1984;60:52–60.

39. Kalala J-P, Benoit D, de Ridder, L. Can recurrence of meningiomas be predicted? Anticancer Res. 2004;24:2319–2324.

40. Roser F, Samii M, Ostertag H, Bellinzona M. The Ki-67 proliferation an- tigen in meningiomas. Experience in 600 cases. Acta Neurochir (Wien). 2004;146(1):37–44.

41. Fujimoto T, Ishida Y, Uchiyama Y, et al. Radiological predictive factors for regrowth of residual benign meningiomas. Neurol Med Chir (Tokyo). 2011;51(6):415–422.

42. Perez-Magan E, Campos-Martin Y, Mur P, et al. Genetic alterations asso- ciated with progression and recurrence in meningiomas. J Neuropathol Exp Neurol. 2012;71(10):882–893.

43. Sahm F SD, Olar A, Koelsche C, et al. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016;108(5):djv377.

44. Goes P, Santos BFO, Suzuki FS, et al. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma? J Neurooncol. 2018;137(2):331–336.

45. Miyagami M, Kanou T, Nakamura S. [P53 protein expression and pro- liferative potential in non-recurrent and recurrent meningiomas]. No to shinkei. 1996;48(8):719–725.

46. Stafford SL, Pollock, BE. Meningioma radiosurgery: tumor con- trol, outcomes, and complications among 190 consecutive patients. Neurosurgery. 2001;49:1029–1038.

47. Torres RC, Frighetto L, De Salles AA, et al. Radiosurgery and stereo- tactic radiotherapy for intracranial meningiomas. Neurosurg Focus. 2003;14(5):e5.

48. Malik I, Rowe JG, Walton L, Radatz MW, Kemeny AA. The use of stereo- tactic radiosurgery in the management of meningiomas. Br J Neurosurg. 2005;19(1):13–20.

49. Kollová A, Liscák R, Novotný J Jr, Vladyka V, Simonová G, Janousková L. Gamma Knife surgery for benign meningioma. J Neurosurg. 2007;107(2):325–336.

50. Seo Y, Kim DG, Kim JW, Han JH, Chung HT, Paek SH. Long-term outcomes after gamma knife radiosurgery for benign meningioma: a single institution’s experience with 424 patients. Neurosurgery. 2018;83(5):1040–1049.

51. Massager N, De Smedt F, Devriendt D. Long-term tumor control of be- nign intracranial tumors after Gamma Knife radiosurgery in 280 patients followed more than 5 years. Acta Neurol Belg. 2013;113(4):463–467.

52. Jang CK, Jung HH, Chang JH, Chang JW, Park YG, Chang WS. Long-term results of gamma knife radiosurgery for intracranial meningioma. Brain Tumor Res Treat. 2015;3(2):103–107.

53. Kondziolka D, Patel AD, Kano H, Flickinger JC, Lunsford LD. Long-term outcomes after gamma knife radiosurgery for meningiomas. Am J Clin Oncol. 2016;39(5):453–457.

54. Hasegawa H, Hanakita S, Shin M, et al. Single-fractionated stereotactic radiosurgery for intracranial meningioma in elderly patients: 25-year experience at a single institution. Oper Neurosurg (Hagerstown). 2018;14(4):341–350.

55. Ge Y, Liu D, Zhang Z, et al. Gamma knife radiosurgery for intracranial be- nign meningiomas: follow-up outcome in 130 patients. Neurosurg Focus. 2019;46(6):E7.

56. Cornelius JF, Slotty PJ, Steiger HJ, Hänggi D, Polivka M, George B. Malignant potential of skull base versus non-skull base meningiomas: clinical series of 1,663 cases. Acta Neurochir (Wien). 2013;155(3):407–413.

57. Youngblood MW, Duran D, Montejo JD, et al. Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg. 2019:1–10.

58. Yoshida T, Vivatbutsiri P, Morriss-Kay G, Saga Y, Iseki S. Cell lin- eage in mammalian craniofacial mesenchyme. Mech Dev. 2008;125(9–10):797–808.

59. Savardekar AR, Patra DP, Bir S, et al. Differential tumor progression pat- terns in skull base versus non-skull base meningiomas: a critical anal- ysis from a long-term follow-up study and review of literature. World Neurosurg. 2018;112:e74–e83.

60. Gallagher MJ, Jenkinson MD, Brodbelt AR, Mills SJ, Chavredakis E. WHO grade 1 meningioma recurrence: are location and Simpson grade still relevant? Clin Neurol Neurosurg. Feb 2016;141:117–121.

61. Nanda A, Vannemreddy P. Recurrence and outcome in skull base meningiomas: do they differ from other intracranial meningiomas? Skull Base. 2008;18(4):243–252.

62. Mansouri A, Klironomos G, Taslimi S, et al. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas. J Neurosurg. 2016;125(2):431–440.

63. Krayenbühl N, Pravdenkova S, Al-Mefty O. De novo versus trans- formed atypical and anaplastic meningiomas: comparisons of clin- ical course, cytogenetics, cytokinetics, and outcome. Neurosurgery. 2007;61(3):495–503.

64. Peyre M, Gauchotte G, Giry M, et al. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. Neuro Oncol. 2018;20(8):1113–1121.

65. Zhao P, Hu M, Zhao M, Ren X, Jiang Z. Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. Neurosurg Rev. 2015;38(1):101–107.

66. Champeaux C, Wilson E, Brandner S, Shieff C, Thorne L. World Health Organization grade III meningiomas. a retrospective study for outcome and prognostic factors assessment. Br J Neurosurg. 2015;29(5):693–698.

67. Koh EJ. Malignant progression of meningioma: a retrospective obser- vational study. http://hdl.handle.net/10371/137988. 2017. Accessed February 6, 2020.

参考文献をもっと見る